
    
      Primary Objective:

      To determine dose-limiting toxicity of CK0801 as defined as any of the events each start at
      the time of CK00801 infusion

        1. Severe (grade 3 or 4) infusion toxicity within 24 hours (NCI-CTCAE V4.0)

        2. Regimen related death within 30 days

        3. Severe (grade 3 or 4) Cytokine Release Syndrome within 30 days

      Secondary Objective:

        1. Preliminary assessment of disease-specific response

        2. Duration of disease-specific response
    
  